today show semaglutide Weight loss drugs help change stigmas around obesity In a new study, Ozempic-maker

Large human single-cell and multi-region brain atlases now show that glial immune programs in Alzheimers disease are highly context-dependentvarying across brain regions, metabolic states, and local neural activity

The SELECT trial, published in The Lancet (October 22, 2025), provides a landmark analysis confirming that the cardioprotective benefits of semaglutide extend beyond weight loss alone. The SELECT Trial: Study Overview The SELECT trial (NCT03574597) enrolled 17,604 participants aged 45 years and above across 41 countries and 804 sites

Of course, theyve been used for quite some time when it comes to diabetes

Kakutani-Hatayama M et al

External resources For researchers serious about understanding the full landscape of GLP-1 medications and weight loss peptides, SeekPeptides offers the most comprehensive educational resource available